Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c.

Slides:

Advertisements

Similar presentations

Camacho et al, Fig. S1 a c e b d f

Advertisements

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Metabolic effects of TUG‐891 are reduced or absent in GPR120‐deficient mice Metabolic effects of TUG‐891 are reduced or absent in GPR120‐deficient mice.

Effects of senescent cells on activity.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 5 Local gel scaffold for T cell memory response.

Activation of PBN and CeA by illuminating the hindpaw after PNI

Antitumor effects of FF and gemcitabine on two pancreatic PDX models.

Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies in athymic nude mice bearing the s.c. Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies.

Activity of MAC-321 (i. v. and p. o

Cyp8b1−/− mice have improved islet insulin secretion and increased islet insulin content but unchanged β-cell mass. Cyp8b1−/− mice have improved islet.

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells.

Fig. 3 Exercise training enhances neuronal activity in vivo.

Glucose tolerance in WT and TRPM2-KO mice.

Fig. 2 Exercise training potentiates synaptic transmissions via mTOR activation. Exercise training potentiates synaptic transmissions via mTOR activation.

Insulin sensitivity in athletes and sedentary normal-weight and obese, young, and old individuals. Insulin sensitivity in athletes and sedentary normal-weight.

A: Chemical structure of pterosin A

Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance. Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Pioglitazone administration acutely inhibits insulin secretion and increases insulin clearance in Wistar rats. Pioglitazone administration acutely inhibits.

Tactile allodynia with activation of dorsal horn neuron in atopy model mice. Tactile allodynia with activation of dorsal horn neuron in atopy model mice.

PTZ-induced neuronal activity visualized by IEGs

Astroglial activation in distinct sites of the spinal cord from mice with bronchial asthma or atopic dermatitis on the back skin at the thoracic spinal.

Antitumor immunity caused by DS-8201a.

Effect of HA on hematopoietic recovery in tumor-bearing mice.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,

Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea and weight loss. Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea.

Stereotactic radiotherapy increases Tregs in tumors.

Cytokine expression in the ileum and colon.

Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

Histone modification status at the Tβ4 promoter and at the protein level in the HuH7 sublines. Histone modification status at the Tβ4 promoter and at the.

GA reduces the growth of Caki-1 tumor xenografts.

5FU-induced specific activation of CD8+ T cells.

In vivo efficacy of targeted EDVTM in an orthotopic neuroblastoma mouse model with high EGFR protein levels. In vivo efficacy of targeted EDVTM in an orthotopic.

Fig. 4 Dox-CBD-SA treatment shows reduced toxicity.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

STINGa enhances mAb immunotherapy in BCL1 lymphoma in an FcγR-dependent manner. STINGa enhances mAb immunotherapy in BCL1 lymphoma in an FcγR-dependent.

Xenograft regrowth studies.

Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.

Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing BALB/c mice following VP-16 pretreatment. Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing.

Neutralization of CSF1 and Ad5-HRG treatment.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.

A, tumor growth studies in H1975 tumor–bearing mice.

Induction of liver NQO1 activity in juvenile female rats treated for 3 d (10 mg/kg qd SERMs or 0.1 mg/kg qd E2 or vehicle control). Induction of liver.

CRA inhibits the growth of human tumor xenografts in vivo.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Mean cell number in small intestinal crypt (a), small intestinal villus (b), and midcolonic crypt (c) of BALB/c (♦) and DBA/2 (▪) mice after two injections.

Apoptotic cell index percentage (a and b) and mitotic cell index percentage (c and d) in small intestinal (a and c) and midcolonic (b and d) crypts of.

YH25448 less suppresses WT EGFR than osimertinib in vivo.

Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Wild-type mice weight following 6-thio-dG and 6-thioguanine treatment.

Biodistributions 24 hours after injection of different 177Lu-chCE7F(ab′)2 conjugates ( MBq, 13 μg) in tumor-bearing nude mice: effect of the number.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

In vivo tumor targeting and biodistribution of radiolabeled anti-CEA Fab-H-2Kb/ova conjugates. In vivo tumor targeting and biodistribution of radiolabeled.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

PDL192 and inhibit the growth of xenograft tumors.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Heterozygous Pik3caH1047R oncogenic mutation causes invasive prostate cancer in mice that does not phenocopy Pten deletion. Heterozygous Pik3caH1047R oncogenic.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

Ex vivo profiling of PD-1 blockade using MDOTS

Trametinib and combination decrease T-lymphocyte proliferation.

Presentation transcript:

Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c mice and (B) of 125I-labeled chTNT-3 administered 1 day after 5-FU (50 mg/kg) in LS174T-bearing nude mice. Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c mice and (B) of 125I-labeled chTNT-3 administered 1 day after 5-FU (50 mg/kg) in LS174T-bearing nude mice. Error bars, SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 as determined using one-way ANOVA followed by Tukey post-hoc test (A) and two-tailed Student t test (B). n = 4 mice for all groups. Julie K. Jang et al. Mol Cancer Ther 2013;12:2827-2836 ©2013 by American Association for Cancer Research